Ayşe BURUŞ, Başak ÇELTİKÇİ, Yasemin AKSOY

The Inflammatory Processes Driven by Gut Microbiota

Microbiome studies have shown alterations in bacterial communities in the state of many diseases, including inflammatory bowel disease, metabolic disorders, autoimmune diseases, neurodegenerative diseases, and cancer. Chronic inflammation is a common promoter of many of these pathological processes. Shifting in the microbial diversity is also known as dysbiosis. Dysbiosis, increased detrimental bacterial products, decreased favorable microbial metabolites, interrupted tissue barriers, and bacterial translocation cause excessive immune response and inflammation. Several mechanisms play a role to maintain intestinal homeostasis by limiting bacterial translocation from the intestinal lumen into the lamina propria. Among these mechanisms, most importantly, the mucosal barrier that consists of the antimicrobial peptides, mucus, and immunoglobulin A is fundamental to protect epithelial barrier integrity to reduce the excessive immune response. Moreover, recognizing bacteria and metabolites through receptors results in T cell regulation and immune modulation, which is the keystone of the controlled immune response. This review summarizes the anti-inflammatory and pro-inflammatory mechanisms driven by gastrointestinal microbiota, and it also highlights the recent approaches, including epigenetics and precision medicine.

PDF

___

[1] Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev. 2012; 70(1): 38-44.

[2] Pasolli E, Asnicar F, Manara S, et al. Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. Cell. 2019; 176(3): 649-662.

[3] Tang L. In vitro intestine model for gut microbiome. Nat Methods. 2019;16(7):578.

[4] Integrative HMPRNC. The Integrative Human Microbiome Project. Nature. 2019; 569(7758): 641-648.

[5] Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011; 479(7374): 538-541.

[6] Clavel T, Desmarchelier C, Haller D, et al. Intestinal microbiota in metabolic diseases: from bacterial community structure and functions to species of pathophysiological relevance. Gut Microbes. 2014; 5(4): 544-551.

[7] Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020; 145(1): 16-27.

[8] Vivarelli S, Salemi R, Candido S, et al. Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers (Basel). 2019; 11(1): 38.

[9] Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6): 918-934.

[10] Kemp WL, Burns DK, Brown TG. 1st Ed. Inflammation and Repair. In: Pathology: The Big Picture. New York, NY; The McGraw-Hill Companies, 2008: 13-22.

[11] Blander JM, Longman RS, Iliev ID, Sonnenberg GF, et al. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017; 18(8): 851-860.

[12] Jandhyala SM, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota. World J Gastroenterol. 2015; 21(29): 8787-8803.

[13] Tap J, Mondot S, Levenez F, et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol. 2009; 11(10): 2574-2584.

[14] Kriss M, Hazleton KZ, Nusbacher NM, et al. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. 2018; (44): 34-40.

[15] Farre R, Fiorani M, Abdu Rahiman S, et al. Intestinal Permeability, Inflammation and the Role of Nutrients. Nutrients. 2020; 12(4): 1185.

[16] Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11(8): 506-514.

[17] Tsilingiri K, Barbosa T, Penna G, et al. Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. Gut. 2012; 61(7): 1007-1015.

[18] Kogut MH, Lee A, Santin E. Microbiome and pathogen interaction with the immune system. Poult Sci. 2020; 99(4): 1906-1913.

[19] Pastorelli L, De Salvo C, Mercado JR, et al. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 2013; (4): 280.

[20] Marchiando AM, Shen L, Graham WV, et al. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology. 2011; 140(4): 1208-1218.

[21] Wilmore JR, Gaudette BT, Gomez Atria D, et al. Commensal Microbes Induce Serum IgA Responses that Protect against Polymicrobial Sepsis. Cell Host Microbe. 2018; 23(3): 302-311.

[22] Simons A, Alhanout K, Duval RE. Bacteriocins, Antimicrobial Peptides from Bacterial Origin: Overview of Their Biology and Their Impact against Multidrug-Resistant Bacteria. Microorganisms. 2020; 8(5): 639.

[23] Parada Venegas D, De la Fuente MK, Landskron G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019; (10): 277.

[24] Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1): 16- 34.

[25] Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012; 13(4): 325-332.

[26] Tanoue T, Morita S, Plichta DR, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019; 565(7741): 600-605.

[27] Hapfelmeier S, Lawson MA, Slack E, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010; 328(5986): 1705-1709.

[28] Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011; 331(6015): 337-341.

[29] Ahern PP, Maloy KJ. Understanding immune-microbiota interactions in the intestine. Immunology. 2020; 159(1): 4-14.

[30] Wu C, Sartor RB, Huang K, et al. Transient activation of mucosal effector immune responses by resident intestinal bacteria in normal hosts is regulated by interleukin-10 signalling. Immunology. 2016; 148(3): 304-314.

[31] Zurita-Turk M, Mendes Souza B, Prosperi de Castro C, et al. Attenuation of intestinal inflammation in IL-10 deficient mice by a plasmid carrying Lactococcus lactis strain. BMC Biotechnol. 2020; 20(1): 38.

[32] Mishima Y, Oka A, Liu B, et al. Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10-producing regulatory B cells. J Clin Invest. 2019; 129(9): 3702-3716.

[33] Zhao Y, Chen F, Wu W, et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol. 2018; 11(3): 752-762.

[34] Sun M, Wu W, Chen L, et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat Commun. 2018; 9(1): 3555.

[35] Ramakrishna C, Kujawski M, Chu H, et al. Bacteroides fragilis polysaccharide A induces IL-10 secreting B and T cells that prevent viral encephalitis. Nat Commun. 2019; 10(1): 2153.

[36] Quevrain E, Maubert MA, Michon C, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut. 2016; 65(3): 415-425.

[37] Lopez-Siles M, Duncan SH, Garcia-Gil LJ, et al. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017; 11(4): 841-852.

[38] Xu J, Liang R, Zhang W, et al. Faecalibacterium prausnitziiderived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes. 2020; 12(3): 224-236.

[39] Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011; 473(7346): 174-180.

[40] David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484): 559-563.

[41] DeGruttola AK, Low D, Mizoguchi A, et al. Current Understanding of Dysbiosis in Disease in Human and Animal Models. Inflamm Bowel Dis. 2016; 22(5): 1137- 1150.

[42] Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 2017; 74(16): 2959- 2977.

[43] Wen L, Duffy A. Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J Nutr. 2017; 147(7): 1468-1475.

[44] Dahmus JD, Kotler DL, Kastenberg DM, et al. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. J Gastrointest Oncol. 2018; 9(4): 769-777.

[45] Shin W, Kim HJ. Intestinal barrier dysfunction orchestrates the onset of inflammatory host-microbiome cross-talk in a human gut inflammation-on-a-chip. Proc Natl Acad Sci. 2018; 115(45): 10539-10547.

[46] Ahluwalia B, Moraes L, Magnusson MK, et al. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018; 53(4): 379-389.

[47] Mishima Y, Sartor RB. Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases. J Gastroenterol. 2020; 55(1): 4-14.

[48] Jeon JH, Ahn KB, Kim SK, et al. Bacterial flagellin induces IL-6 expression in human basophils. Mol Immunol. 2015; 65(1): 168-176.

[49] Rolli J, Loukili N, Levrand S, et al. Bacterial flagellin elicits widespread innate immune defense mechanisms, apoptotic signaling, and a sepsis-like systemic inflammatory response in mice. Crit Care. 2010; 14(4): 160.

[50] Shikama Y, Kuroishi T, Nagai Y, et al. Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macrophages to produce pro-IL-1beta and by down-regulation of the suppressor of cytokine signaling 1 (SOCS1). Innate Immun. 2011; 17(1) :3-15.

[51] Kaneko N, Kurata M, Yamamoto T, et al. The role of interleukin-1 in general pathology. Inflamm Regen. 2019; (39): 12.

[52] Mailer RK, Joly AL, Liu S, et al. IL-1beta promotes Th17 differentiation by inducing alternative splicing of FOXP3. Sci Rep. 2015; (5): 14674.

[53] Lin YD, Arora J, Diehl K, et al. Vitamin D Is Required for ILC3 Derived IL-22 and Protection From Citrobacter rodentium Infection. Front Immunol. 2019; (10): 1.

[54] Zeng B, Shi S, Ashworth G, et al. ILC3 function as a doubleedged sword in inflammatory bowel diseases. Cell Death Dis. 2019; 10(4): 315.

[55] Hersoug LG, Moller P, Loft S. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity. Nutr Res Rev. 2018; 31(2): 153-163.

[56] Knox NC, Forbes JD, Peterson CL, et al. The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases. Am J Gastroenterol. 2019; 114(7): 1051-1070.

[57] Zhu W, Winter MG, Byndloss MX, et al. Precision editing of the gut microbiota ameliorates colitis. Nature. 2018; 553(7687): 208-211.

[58] Khan I, Ullah N, Zha L, et al. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019; 8(3): 126.

[59] Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17- mediated tumour growth. Nature. 2012; 491(7423): 254- 258.

[60] Miro-Blanch J, Yanes O. Epigenetic Regulation at the Interplay Between Gut Microbiota and Host Metabolism. Front Genet. 2019; (10): 638.

[61] Corte V, Andrade AC, Diaz-Bulnes P, et al. Microbiota derived short chain fatty acids, propionate and butyrate, contribute to modulate the inflammatory response in chronic kidney disease. Nephrol Dial Transplant. 2020; 35(Suppl. 3): 147.